Very good partial response in a patient with MALT-lymphoma of the lung after treatment with low-dose thalidomide

Leukemia and Lymphoma

Volumn 46, Issue 9, 2005, Pages 1379-1382

  Kees, Mathias ^a   Raderer, Markus ^a   Metz Schimmerl, Sylvia ^a   Chott, Andreas ^a   Gisslinger, Heinz ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biological cancer therapy; Extranodal MALT lymphoma; Low dose thalidomide

Indexed keywords

IMMUNOGLOBULIN KAPPA CHAIN; PREDNISONE; THALIDOMIDE;

ADULT; ARTICLE; BRONCHOGRAPHY; BRONCHOSCOPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DYSESTHESIA; HUMAN; LOW DRUG DOSE; LUNG BIOPSY; LUNG CANCER; LUNG RESECTION; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SERODIAGNOSIS; THORAX RADIOGRAPHY; XEROSTOMIA;

HUMANS; LUNG NEOPLASMS; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MALE; MIDDLE AGED; THALIDOMIDE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 24644458895     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500144649     Document Type: Article

References (12)

1. Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997; 8:727-737.
2. Zucca E, Roggero E, Bertoni F, Conconi A, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol 1999;10:1023-1033.
3. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-577.
4. Baldini L, Blini M, Guffanti A, et al. Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. Ann Oncol 1998;9:779-781.
5. Raderer M, Jager G, Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003;65:306-310.
6. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-2745.
7. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
8. Kees M, Dimou G, Sillaber C, et al. Low dose thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2003;44:1943-1946.
9. Fanelli M, Sarmiento R, Gattuso D, et al. Thalidomide: a new anticancer drug? Expert Opin Investig Drugs 2003;12:1211-1225.
10. Benchikhi H, Bodemer C, Fraitag S, et al. Treatment of cutaneous lymphoid hyperplasia with thalidomide: report of two cases. J Am Acad Dermatol 1999;40:1005-1007.
11. Wohrer S, Drach J, Hejna M, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol 2003;14:1758-1761.
12. Raderer M, Isaacson PG. Extranodal lymphoma of MALT-type: perspective at the beginning of the 21st century. Expert Rev Anticancer Ther 2001;1:53-64.